| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 44 | 2023 | 706 | 9.270 |
Why?
|
| Transcription, Genetic | 32 | 2022 | 578 | 6.350 |
Why?
|
| Anemia, Sickle Cell | 25 | 2023 | 183 | 6.330 |
Why?
|
| Protein Phosphatase 1 | 21 | 2024 | 62 | 4.940 |
Why?
|
| Gene Expression Regulation, Viral | 15 | 2021 | 110 | 3.880 |
Why?
|
| Cyclin-Dependent Kinase 9 | 17 | 2021 | 37 | 3.700 |
Why?
|
| Virus Replication | 22 | 2024 | 278 | 2.880 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 17 | 2021 | 53 | 2.760 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2023 | 169 | 2.620 |
Why?
|
| HIV Infections | 18 | 2023 | 2303 | 2.450 |
Why?
|
| Cyclin-Dependent Kinase 2 | 12 | 2018 | 31 | 2.420 |
Why?
|
| Phosphorylation | 27 | 2024 | 928 | 2.140 |
Why?
|
| Gene Products, tat | 12 | 2010 | 35 | 2.110 |
Why?
|
| Phosphoprotein Phosphatases | 8 | 2010 | 46 | 1.920 |
Why?
|
| Antiviral Agents | 7 | 2022 | 157 | 1.740 |
Why?
|
| Sickle Cell Trait | 2 | 2022 | 17 | 1.630 |
Why?
|
| Ebolavirus | 4 | 2019 | 42 | 1.590 |
Why?
|
| Urea | 5 | 2020 | 41 | 1.420 |
Why?
|
| Iron Chelating Agents | 5 | 2017 | 21 | 1.420 |
Why?
|
| Orosomucoid | 2 | 2020 | 12 | 1.360 |
Why?
|
| Anti-HIV Agents | 6 | 2017 | 420 | 1.320 |
Why?
|
| Indoles | 5 | 2020 | 158 | 1.290 |
Why?
|
| Humans | 94 | 2024 | 37093 | 1.240 |
Why?
|
| RNA Polymerase II | 7 | 2010 | 29 | 1.210 |
Why?
|
| Serine | 5 | 2018 | 75 | 1.190 |
Why?
|
| HIV Long Terminal Repeat | 6 | 2021 | 20 | 1.150 |
Why?
|
| Macrophages | 7 | 2020 | 439 | 1.010 |
Why?
|
| Polycythemia | 9 | 2020 | 15 | 1.010 |
Why?
|
| Host-Pathogen Interactions | 7 | 2020 | 186 | 1.000 |
Why?
|
| Cation Transport Proteins | 4 | 2012 | 34 | 0.970 |
Why?
|
| RNA, Viral | 12 | 2024 | 301 | 0.900 |
Why?
|
| Viral Proteins | 9 | 2024 | 174 | 0.890 |
Why?
|
| Cell Line | 17 | 2024 | 1354 | 0.880 |
Why?
|
| Nucleoproteins | 2 | 2019 | 11 | 0.870 |
Why?
|
| Iron | 10 | 2023 | 225 | 0.800 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 15 | 0.800 |
Why?
|
| Protein Binding | 11 | 2021 | 972 | 0.760 |
Why?
|
| Quinolines | 1 | 2020 | 64 | 0.730 |
Why?
|
| Leukocytes, Mononuclear | 10 | 2023 | 234 | 0.720 |
Why?
|
| Neutrophil Infiltration | 1 | 2020 | 27 | 0.720 |
Why?
|
| Lung | 2 | 2020 | 446 | 0.720 |
Why?
|
| Viral Core Proteins | 1 | 2019 | 10 | 0.710 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 239 | 0.690 |
Why?
|
| RNA Interference | 5 | 2019 | 243 | 0.650 |
Why?
|
| Animals | 24 | 2024 | 15081 | 0.650 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 15 | 0.620 |
Why?
|
| Small Molecule Libraries | 2 | 2021 | 45 | 0.610 |
Why?
|
| Cyclin T | 5 | 2021 | 16 | 0.600 |
Why?
|
| Proviruses | 2 | 2015 | 29 | 0.600 |
Why?
|
| Cells, Cultured | 10 | 2018 | 1518 | 0.590 |
Why?
|
| Mass Spectrometry | 4 | 2018 | 260 | 0.560 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2006 | 27 | 0.560 |
Why?
|
| Mutation | 10 | 2018 | 1095 | 0.540 |
Why?
|
| Isoquinolines | 2 | 2015 | 45 | 0.540 |
Why?
|
| Mutant Proteins | 2 | 2012 | 51 | 0.520 |
Why?
|
| Virus Activation | 1 | 2015 | 35 | 0.520 |
Why?
|
| RNA-Binding Proteins | 3 | 2012 | 146 | 0.520 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2006 | 85 | 0.510 |
Why?
|
| Sulfonamides | 1 | 2015 | 80 | 0.500 |
Why?
|
| Genes, Viral | 2 | 2012 | 63 | 0.490 |
Why?
|
| Thiosemicarbazones | 2 | 2012 | 10 | 0.490 |
Why?
|
| Mice | 10 | 2023 | 5913 | 0.490 |
Why?
|
| Oxygen | 2 | 2020 | 207 | 0.490 |
Why?
|
| I-kappa B Kinase | 1 | 2014 | 44 | 0.470 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 7 | 2017 | 18 | 0.470 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2024 | 767 | 0.460 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2011 | 35 | 0.460 |
Why?
|
| Gene Expression | 6 | 2023 | 674 | 0.460 |
Why?
|
| Hela Cells | 9 | 2012 | 366 | 0.460 |
Why?
|
| Amino Acid Sequence | 7 | 2018 | 1180 | 0.460 |
Why?
|
| Adenovirus E4 Proteins | 1 | 2012 | 2 | 0.430 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2002 | 4 | 0.430 |
Why?
|
| Biocatalysis | 1 | 2012 | 28 | 0.420 |
Why?
|
| Serpins | 1 | 2012 | 27 | 0.420 |
Why?
|
| Proteomics | 5 | 2019 | 325 | 0.420 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 33 | 0.420 |
Why?
|
| Hemolysis | 3 | 2023 | 40 | 0.420 |
Why?
|
| Vero Cells | 7 | 2024 | 93 | 0.420 |
Why?
|
| Eye Proteins | 1 | 2012 | 46 | 0.420 |
Why?
|
| Virion | 3 | 2019 | 69 | 0.410 |
Why?
|
| Female | 25 | 2021 | 20969 | 0.410 |
Why?
|
| Male | 25 | 2021 | 20025 | 0.390 |
Why?
|
| Endothelial Cells | 2 | 2023 | 308 | 0.380 |
Why?
|
| Rift Valley fever virus | 2 | 2024 | 8 | 0.380 |
Why?
|
| Endoribonucleases | 1 | 2010 | 23 | 0.370 |
Why?
|
| RNA, Small Interfering | 5 | 2019 | 409 | 0.370 |
Why?
|
| Hydroxyurea | 3 | 2016 | 34 | 0.370 |
Why?
|
| Models, Molecular | 5 | 2018 | 808 | 0.360 |
Why?
|
| Disease Progression | 3 | 2021 | 601 | 0.350 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2006 | 4 | 0.350 |
Why?
|
| Early Diagnosis | 2 | 2021 | 64 | 0.350 |
Why?
|
| Down-Regulation | 2 | 2011 | 435 | 0.350 |
Why?
|
| Cell Nucleus | 3 | 2012 | 366 | 0.340 |
Why?
|
| Erythropoietin | 6 | 2016 | 39 | 0.330 |
Why?
|
| Inflammation | 5 | 2020 | 618 | 0.330 |
Why?
|
| Adult | 16 | 2023 | 11712 | 0.320 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 617 | 0.310 |
Why?
|
| Middle Aged | 12 | 2023 | 10129 | 0.310 |
Why?
|
| Benzoates | 1 | 2007 | 16 | 0.300 |
Why?
|
| Transcription Factors | 4 | 2019 | 681 | 0.300 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 229 | 0.300 |
Why?
|
| Positive Transcriptional Elongation Factor B | 3 | 2015 | 14 | 0.290 |
Why?
|
| Young Adult | 8 | 2023 | 4268 | 0.290 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 333 | 0.290 |
Why?
|
| Cell Survival | 5 | 2014 | 864 | 0.280 |
Why?
|
| Triazoles | 1 | 2007 | 86 | 0.280 |
Why?
|
| Nucleosides | 1 | 2006 | 30 | 0.280 |
Why?
|
| Hepacivirus | 1 | 2006 | 62 | 0.280 |
Why?
|
| Kidney | 2 | 2020 | 337 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 3 | 2005 | 515 | 0.280 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 12 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2012 | 187 | 0.270 |
Why?
|
| Pyrimidines | 1 | 2006 | 118 | 0.270 |
Why?
|
| Curcumin | 2 | 2017 | 74 | 0.260 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 220 | 0.260 |
Why?
|
| Erythropoiesis | 3 | 2023 | 13 | 0.260 |
Why?
|
| Models, Biological | 4 | 2018 | 677 | 0.260 |
Why?
|
| Adolescent | 7 | 2023 | 5363 | 0.260 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 1568 | 0.250 |
Why?
|
| Catalytic Domain | 2 | 2018 | 109 | 0.250 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 84 | 0.240 |
Why?
|
| Protein Conformation | 2 | 2018 | 389 | 0.240 |
Why?
|
| Proteins | 2 | 2020 | 369 | 0.240 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2013 | 80 | 0.240 |
Why?
|
| Alleles | 3 | 2020 | 321 | 0.230 |
Why?
|
| Up-Regulation | 1 | 2006 | 513 | 0.230 |
Why?
|
| Reticulocytes | 1 | 2023 | 9 | 0.230 |
Why?
|
| Telomere | 1 | 2024 | 56 | 0.230 |
Why?
|
| DNA-Binding Proteins | 3 | 2012 | 539 | 0.230 |
Why?
|
| Mucins | 1 | 2023 | 35 | 0.230 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 10 | 0.230 |
Why?
|
| Aged | 6 | 2021 | 6741 | 0.220 |
Why?
|
| Vascular Diseases | 2 | 2020 | 30 | 0.210 |
Why?
|
| Erythroid Precursor Cells | 2 | 2020 | 7 | 0.210 |
Why?
|
| PPAR alpha | 1 | 2022 | 42 | 0.210 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 893 | 0.210 |
Why?
|
| Fetal Hemoglobin | 2 | 2013 | 14 | 0.200 |
Why?
|
| Protein Kinases | 1 | 2002 | 100 | 0.200 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 357 | 0.200 |
Why?
|
| Kringles | 1 | 2021 | 5 | 0.200 |
Why?
|
| Quantitative Trait Loci | 2 | 2020 | 77 | 0.200 |
Why?
|
| Immunoprecipitation | 4 | 2011 | 131 | 0.200 |
Why?
|
| Cytokines | 2 | 2020 | 602 | 0.200 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2021 | 51 | 0.200 |
Why?
|
| Prognosis | 2 | 2021 | 739 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 197 | 0.190 |
Why?
|
| Drug Stability | 2 | 2018 | 116 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 139 | 0.190 |
Why?
|
| Enzyme Activation | 2 | 2012 | 444 | 0.190 |
Why?
|
| Brain Ischemia | 1 | 2023 | 184 | 0.190 |
Why?
|
| Homozygote | 5 | 2013 | 77 | 0.190 |
Why?
|
| tau Proteins | 1 | 2021 | 167 | 0.190 |
Why?
|
| Viruses | 1 | 2020 | 36 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 259 | 0.180 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 20 | 0.180 |
Why?
|
| Immunophenotyping | 1 | 2020 | 57 | 0.180 |
Why?
|
| Macrophages, Peritoneal | 1 | 2020 | 23 | 0.180 |
Why?
|
| Cyclin E | 2 | 2014 | 13 | 0.180 |
Why?
|
| Nucleocapsid Proteins | 1 | 2019 | 9 | 0.180 |
Why?
|
| NF-kappa B | 2 | 2015 | 339 | 0.180 |
Why?
|
| Organ Specificity | 1 | 2020 | 129 | 0.180 |
Why?
|
| Gene Expression Regulation | 4 | 2024 | 1015 | 0.180 |
Why?
|
| Ribonucleoproteins | 1 | 2019 | 29 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2019 | 16 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2019 | 17 | 0.170 |
Why?
|
| Chiroptera | 1 | 2019 | 20 | 0.170 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2019 | 29 | 0.170 |
Why?
|
| Amino Acid Motifs | 2 | 2012 | 91 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 307 | 0.170 |
Why?
|
| Stroke | 1 | 2023 | 286 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 122 | 0.170 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1207 | 0.170 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2018 | 8 | 0.170 |
Why?
|
| Viral Envelope Proteins | 1 | 2019 | 82 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 610 | 0.170 |
Why?
|
| Marburgvirus | 1 | 2018 | 7 | 0.160 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 1 | 2018 | 9 | 0.160 |
Why?
|
| Ferritins | 4 | 2020 | 55 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2018 | 14 | 0.160 |
Why?
|
| Cytoplasmic Granules | 1 | 2018 | 8 | 0.160 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 18 | 0.160 |
Why?
|
| Hemoglobinuria | 1 | 2018 | 4 | 0.160 |
Why?
|
| Bacteria | 1 | 2021 | 255 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2018 | 8 | 0.160 |
Why?
|
| Inclusion Bodies | 1 | 2018 | 33 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2018 | 15 | 0.160 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2018 | 15 | 0.160 |
Why?
|
| Ubiquitination | 1 | 2018 | 61 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 26 | 0.160 |
Why?
|
| Capsid | 1 | 2018 | 54 | 0.160 |
Why?
|
| Actins | 2 | 2011 | 148 | 0.160 |
Why?
|
| Monocytes | 2 | 2010 | 257 | 0.150 |
Why?
|
| Capsid Proteins | 1 | 2018 | 67 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.150 |
Why?
|
| Cyclins | 2 | 2009 | 37 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2010 | 356 | 0.150 |
Why?
|
| Reverse Transcription | 2 | 2014 | 18 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 173 | 0.150 |
Why?
|
| Genome, Viral | 4 | 2024 | 109 | 0.150 |
Why?
|
| Binding Sites | 3 | 2018 | 651 | 0.150 |
Why?
|
| Cell Proliferation | 4 | 2015 | 1198 | 0.150 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2016 | 4 | 0.150 |
Why?
|
| Jurkat Cells | 4 | 2019 | 79 | 0.140 |
Why?
|
| Heme Oxygenase-1 | 2 | 2015 | 51 | 0.140 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2016 | 2 | 0.140 |
Why?
|
| Thrombospondin 1 | 1 | 2017 | 23 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 1371 | 0.140 |
Why?
|
| Transcriptional Activation | 3 | 2012 | 172 | 0.140 |
Why?
|
| Thrombosis | 1 | 2017 | 63 | 0.140 |
Why?
|
| Protein Phosphatase 2 | 2 | 2006 | 22 | 0.140 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 237 | 0.140 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 57 | 0.130 |
Why?
|
| HL-60 Cells | 1 | 2015 | 32 | 0.130 |
Why?
|
| Apolipoprotein B-100 | 1 | 2015 | 7 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 162 | 0.130 |
Why?
|
| Genotype | 3 | 2013 | 730 | 0.130 |
Why?
|
| Virus Latency | 1 | 2015 | 42 | 0.130 |
Why?
|
| Protein Transport | 2 | 2016 | 302 | 0.130 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 57 | 0.130 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 2 | 2014 | 75 | 0.130 |
Why?
|
| Receptors, Interferon | 1 | 2014 | 14 | 0.130 |
Why?
|
| DNA Replication | 1 | 2016 | 152 | 0.130 |
Why?
|
| Cyclin A | 1 | 2014 | 5 | 0.120 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 19 | 0.120 |
Why?
|
| Antisickling Agents | 2 | 2016 | 15 | 0.120 |
Why?
|
| Molecular Weight | 1 | 2014 | 167 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 55 | 0.120 |
Why?
|
| Purines | 2 | 2012 | 38 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 40 | 0.120 |
Why?
|
| Mice, Knockout | 2 | 2014 | 933 | 0.120 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 201 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2014 | 142 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2014 | 12 | 0.120 |
Why?
|
| COS Cells | 2 | 2005 | 69 | 0.120 |
Why?
|
| Child | 6 | 2023 | 3131 | 0.120 |
Why?
|
| Streptomycin | 1 | 2013 | 4 | 0.120 |
Why?
|
| Glutathione Transferase | 2 | 2005 | 88 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2013 | 11 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2013 | 31 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 421 | 0.120 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2013 | 18 | 0.110 |
Why?
|
| Transfection | 3 | 2015 | 523 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 408 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1130 | 0.110 |
Why?
|
| Plasmids | 2 | 2005 | 246 | 0.110 |
Why?
|
| Macrophage Activation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 70 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2012 | 27 | 0.110 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 46 | 0.110 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 42 | 0.110 |
Why?
|
| Chemokines | 1 | 2013 | 97 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2013 | 83 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2012 | 35 | 0.110 |
Why?
|
| Overweight | 1 | 2015 | 247 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 935 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2012 | 38 | 0.100 |
Why?
|
| Gene Frequency | 1 | 2012 | 195 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 73 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2012 | 151 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 1039 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2015 | 286 | 0.100 |
Why?
|
| Pyridines | 1 | 2012 | 116 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 295 | 0.100 |
Why?
|
| Peptide Mapping | 1 | 2011 | 19 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 196 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2231 | 0.100 |
Why?
|
| Blackwater Fever | 1 | 2011 | 1 | 0.100 |
Why?
|
| Proteome | 1 | 2012 | 144 | 0.100 |
Why?
|
| Point Mutation | 2 | 2009 | 93 | 0.100 |
Why?
|
| Virus Integration | 2 | 2012 | 58 | 0.100 |
Why?
|
| Child, Preschool | 5 | 2020 | 1418 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2012 | 125 | 0.090 |
Why?
|
| Threonine | 1 | 2010 | 25 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 58 | 0.090 |
Why?
|
| Rift Valley Fever | 2 | 2024 | 7 | 0.090 |
Why?
|
| Malaria, Cerebral | 1 | 2011 | 31 | 0.090 |
Why?
|
| Blotting, Western | 3 | 2012 | 859 | 0.090 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2010 | 8 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 352 | 0.090 |
Why?
|
| Russia | 4 | 2013 | 25 | 0.090 |
Why?
|
| Rabbits | 1 | 2010 | 283 | 0.090 |
Why?
|
| Biological Transport | 1 | 2010 | 185 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 623 | 0.090 |
Why?
|
| Malaria, Falciparum | 1 | 2011 | 90 | 0.090 |
Why?
|
| Sp1 Transcription Factor | 1 | 2009 | 48 | 0.090 |
Why?
|
| Peptides | 1 | 2012 | 320 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 161 | 0.080 |
Why?
|
| Kinetics | 2 | 2013 | 708 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 540 | 0.080 |
Why?
|
| Iron, Dietary | 1 | 2008 | 13 | 0.080 |
Why?
|
| CDC2 Protein Kinase | 1 | 2008 | 17 | 0.080 |
Why?
|
| RNA Splicing | 1 | 2008 | 40 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2008 | 12 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1378 | 0.080 |
Why?
|
| Homocysteine | 1 | 2008 | 19 | 0.080 |
Why?
|
| Dipeptides | 1 | 2008 | 32 | 0.080 |
Why?
|
| Isoniazid | 1 | 2007 | 5 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 643 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2023 | 190 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 515 | 0.070 |
Why?
|
| Gene Products, rev | 1 | 2006 | 4 | 0.070 |
Why?
|
| Karyopherins | 1 | 2006 | 6 | 0.070 |
Why?
|
| Glutathione | 1 | 2008 | 179 | 0.070 |
Why?
|
| RNA Helicases | 1 | 2006 | 16 | 0.070 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2006 | 29 | 0.070 |
Why?
|
| Chromatography, Liquid | 2 | 2021 | 142 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 59 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2006 | 136 | 0.070 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2018 | 22 | 0.070 |
Why?
|
| Receptors, Transferrin | 1 | 2006 | 15 | 0.070 |
Why?
|
| Systole | 1 | 2006 | 61 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 31 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2015 | 1492 | 0.070 |
Why?
|
| Endothelin-1 | 1 | 2006 | 55 | 0.070 |
Why?
|
| Phosphorylase a | 1 | 2005 | 2 | 0.070 |
Why?
|
| Biotinylation | 1 | 2005 | 11 | 0.070 |
Why?
|
| Genes, tat | 1 | 2005 | 8 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 974 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 935 | 0.070 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 35 | 0.070 |
Why?
|
| Valine | 1 | 2005 | 31 | 0.070 |
Why?
|
| Phenylalanine | 1 | 2005 | 25 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 132 | 0.070 |
Why?
|
| Apoptosis | 3 | 2014 | 1398 | 0.070 |
Why?
|
| Cyclin D1 | 1 | 2005 | 43 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2006 | 212 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 83 | 0.070 |
Why?
|
| Cyclin H | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 40 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 50 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 252 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2007 | 381 | 0.060 |
Why?
|
| Casein Kinase Ialpha | 1 | 2024 | 2 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 2379 | 0.060 |
Why?
|
| K562 Cells | 1 | 2024 | 32 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2018 | 753 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2007 | 362 | 0.060 |
Why?
|
| Neutrophils | 2 | 2020 | 131 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2023 | 30 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 519 | 0.060 |
Why?
|
| Erythroblasts | 1 | 2023 | 2 | 0.060 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2015 | 33 | 0.060 |
Why?
|
| Dependovirus | 1 | 2003 | 12 | 0.060 |
Why?
|
| Glycosylation | 1 | 2023 | 100 | 0.060 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2023 | 55 | 0.060 |
Why?
|
| Brazil | 1 | 2023 | 64 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 158 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 109 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2002 | 8 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 190 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2014 | 58 | 0.050 |
Why?
|
| Infant | 3 | 2011 | 1046 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2020 | 7 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2015 | 107 | 0.050 |
Why?
|
| Mannose | 1 | 2020 | 25 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2002 | 272 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2020 | 58 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2020 | 77 | 0.050 |
Why?
|
| Pulmonary Fibrosis | 1 | 2020 | 31 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 182 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2023 | 1908 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 113 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2019 | 43 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 311 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 803 | 0.040 |
Why?
|
| Hospitals, Special | 1 | 2018 | 3 | 0.040 |
Why?
|
| Congo | 1 | 2018 | 3 | 0.040 |
Why?
|
| Patient Care | 1 | 2018 | 29 | 0.040 |
Why?
|
| Autophagy | 1 | 2019 | 116 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2721 | 0.040 |
Why?
|
| Sequence Homology | 1 | 2018 | 34 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 195 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2020 | 587 | 0.040 |
Why?
|
| United States | 2 | 2020 | 4223 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 114 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 54 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2015 | 53 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 54 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 441 | 0.030 |
Why?
|
| Virulence | 1 | 2016 | 223 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 138 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2015 | 81 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1455 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 922 | 0.030 |
Why?
|
| Brain | 1 | 2021 | 1346 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 205 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2013 | 5 | 0.030 |
Why?
|
| Streptomyces | 1 | 2013 | 16 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 93 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 45 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 145 | 0.030 |
Why?
|
| Croatia | 1 | 2013 | 4 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 77 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 79 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 168 | 0.030 |
Why?
|
| Granulocytes | 1 | 2013 | 29 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 201 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 93 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 626 | 0.030 |
Why?
|
| Virus Release | 1 | 2012 | 9 | 0.030 |
Why?
|
| Family Health | 1 | 2013 | 56 | 0.030 |
Why?
|
| Plant Roots | 1 | 2015 | 158 | 0.030 |
Why?
|
| Registries | 1 | 2014 | 335 | 0.030 |
Why?
|
| Isomerism | 1 | 2012 | 63 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2013 | 149 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 52 | 0.030 |
Why?
|
| Haplotypes | 1 | 2013 | 182 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2012 | 59 | 0.030 |
Why?
|
| Virus Assembly | 1 | 2012 | 41 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 52 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 61 | 0.030 |
Why?
|
| Electroporation | 1 | 2011 | 18 | 0.020 |
Why?
|
| Insulin | 1 | 2013 | 236 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2011 | 29 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 353 | 0.020 |
Why?
|
| Zambia | 1 | 2011 | 40 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2012 | 492 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 997 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 453 | 0.020 |
Why?
|
| Africa | 1 | 2010 | 76 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 689 | 0.020 |
Why?
|
| Chromatin | 1 | 2011 | 169 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 399 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 623 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 326 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 2011 | 135 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2009 | 30 | 0.020 |
Why?
|
| Interleukins | 1 | 2009 | 29 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 88 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 19 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 30 | 0.020 |
Why?
|
| Hemeproteins | 1 | 2008 | 14 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 583 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2008 | 8 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 180 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 455 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 10 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 373 | 0.020 |
Why?
|
| Altitude | 1 | 2006 | 6 | 0.020 |
Why?
|
| Reticulocyte Count | 1 | 2006 | 3 | 0.020 |
Why?
|
| Zimbabwe | 1 | 2006 | 5 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 333 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 212 | 0.020 |
Why?
|
| Piperidines | 1 | 2006 | 77 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2006 | 156 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2006 | 153 | 0.020 |
Why?
|
| Flavonoids | 1 | 2006 | 87 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 149 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2008 | 646 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 3562 | 0.010 |
Why?
|